Compare MP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | SYRE |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.5B |
| IPO Year | 2020 | 2015 |
| Metric | MP | SYRE |
|---|---|---|
| Price | $59.39 | $103.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $75.25 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 6.9M | 807.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $331,952,000.00 | N/A |
| Revenue This Year | $100.51 | N/A |
| Revenue Next Year | $60.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.15 | N/A |
| 52 Week Low | $37.81 | $14.51 |
| 52 Week High | $100.25 | $108.14 |
| Indicator | MP | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 56.06 |
| Support Level | $51.86 | $92.37 |
| Resistance Level | $64.62 | $105.09 |
| Average True Range (ATR) | 3.09 | 5.82 |
| MACD | 1.99 | -0.40 |
| Stochastic Oscillator | 91.33 | 69.63 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.